Stifel Nicolaus Issues Pessimistic Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health (NYSE:ELAN - Free Report) had its price target cut by Stifel Nicolaus from $15.00 to $13.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley decreased their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. UBS Group cut their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler lowered their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, Barclays reduced their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $14.67.

Elanco Animal Health Stock Up 4.2 %

Shares of ELAN traded up $0.34 during trading hours on Monday, hitting $8.44. The company had a trading volume of 5,406,589 shares, compared to its average volume of 4,918,932. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $4.19 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health has a one year low of $8.02 and a one year high of $18.80. The company's fifty day moving average price is $10.26 and its two-hundred day moving average price is $11.84.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business's quarterly revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 earnings per share. As a group, equities analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.89% of the company's stock.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds have recently bought and sold shares of the business. Hillsdale Investment Management Inc. grew its stake in Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock valued at $524,000 after acquiring an additional 900 shares during the period. Arizona State Retirement System increased its stake in shares of Elanco Animal Health by 0.8% during the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock worth $1,737,000 after purchasing an additional 1,166 shares in the last quarter. MTM Investment Management LLC raised its position in shares of Elanco Animal Health by 9.3% during the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after purchasing an additional 1,200 shares during the last quarter. M&T Bank Corp lifted its stake in Elanco Animal Health by 5.9% in the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company's stock valued at $388,000 after buying an additional 1,464 shares in the last quarter. Finally, Freedom Investment Management Inc. boosted its holdings in Elanco Animal Health by 9.1% in the 4th quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock worth $251,000 after buying an additional 1,725 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.